Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorCentre Hospitalier Universitaire de Nīmes
About this trial
Overexpression of inhibitors of apoptosis proteins (IAPs) in patients treated for locally advanced cervical cancer with exclusive radio-chemotherapy may have a prognostic role on the local recurrence rate at 24 months.
Eligibility criteria
Qualifiers
Patients treated with the exclusive radio-chemotherapy combination for locally advanced cervical carcinoma (stage Ib-IVb according to FIGO classification).
Patients aged ≥ 18 years.
Patients with a minimum of 2 years post-treatment follow-up.
Patients for whom the initial biopsy specimen (before treatment) is available.
Disqualifiers
Patients under court protection, guardianship or curatorship.
Trial design
Treatments tested in this trial
- Immunohistochemistry
Treatment groups
No treatment groups listed
Sponsors and collaborators
Centre Hospitalier Universitaire de Nīmes
Lead sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Collaborator
Source ClinicalTrials.gov